SEARCH

SEARCH BY CITATION

We would like to thank Drs. Trock and Walsh for their insightful comments regarding our study. The use of salvage radiation and salvage hormonal therapy were modeled as time-dependent covariates. We did not specifically look at whether the reduction in risk of all-cause mortality depended upon the value of PSA doubling time, stratified by <6 months vs≥6 months, as in their analysis. A current study is being performed that addresses the issue of possible benefit in the PSA DT subgroups stratified to compute the 6-month value.

REFERENCES

  1. Top of page
  • 1
    Choueiri TK, Chen MH, D'Amico AV, et al. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010; 116: 1887-1892.
  • 2
    Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299: 2760-2769.
  • 3
    Trock BJ, Han M, Freedland SJ, Humphreys EB, Partin AW, Walsh PC. Impact of salvage androgen deprivation therapy on overall survival in men with biochemical recurrence after radical prostatectomy (Proc Amer Urol Assoc 2009). J Urol. 2009; 181: 458.

Toni K. Choueiri MD*, Anthony V. D'Amico MD, PhD*, Ming-Hui Chen PhD†, * Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachussetts, † University of Connecticut, Storrs, Connecticut.